Canadian Sciences Speakers Network

Réseau Canadien de Panélistes Scientifiques


Sylvie Mader: Profile Photo

Sylvie Mader

Montreal, Quebec

Position: Full Professor at UdeM – Institute for Research in Immunology and Cancer

Organization: Université de Montréal

After training at the École normale supérieure de Paris, the Université de Paris VI and at the Institut Pasteur, Sylvie Mader joined Pierre Chambon’s team at the Louis Pasteur Université in Strasbourg for a Ph.D. in Biochemistry in 1987, which she completed in 1991. She then joined Nahum Sonenberg’s team, at McGill University, for postdoctoral training where she brought to light a control mechanism of translation involving eIF4E. She joined the Université de Montréal in 1995 and was recruited in 2005 by the Institute for Research in Immunology and Cancer, where she heads the Molecular Targeting in Breast Cancer research unit.

Areas of Expertise:

+ Cancer
+ Transcription
+ Ubiquitination, SUMOylation

Language(s):

+ English
+ French


My Work

What I do:

Sylvie Mader and her team try to identify the causes of the diversity of mammary tumors and how they impact tumor responses to the drugs used in breast cancer treatment. The group strives to better understand drug resistance mechanisms and to identify new therapeutic targets and strategies to optimize breast cancer treatment.

Ask me about:

N/A

Why me:

N/A

Fun facts:

N/A


About Me

Sector: Academia (Post Secondary)

English proficiency: Read, Write, Speak

French proficiency: Read, Write, Speak

Pronouns: She/Her/Hers

Gender: Female

Demographic: European / White


Recent Publications

Title Year
SLIT-ROBO signalling promotes pancreatic tumour – endothelial crosstalk2024
IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition2024
The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens2022
CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA32022
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells2022
Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat2021
Studying the Genomic Role of Cathepsin-D in ER+ Breast Cancer2021
Abstract 4375: Inhibition of triple negative breast cancer cell progression using estrogen related receptor alpha endogenous ligands2020
Isolation and functional characterization of a novel endogenous inverse agonist of estrogen related receptors (ERRs) from human pregnancy urine2019
SUN-011 Identification Of Regulators Of Estrogenic Signalling In ER-positive Breast Cancer Cells By Whole Genome shRNA Screening2019
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells2018
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen – A new hybrid design paradigm2018
Abstract 4670: Evidence of neoantigen-reactive T cell response in a case of relapsing, mismatch-repair gene proficient, colorectal cancer2018
Monitoring ligand-dependent assembly of receptor ternary complexes in live cells by BRETFect2018
Abstract P5-07-12: miR-34a as a prognostic biomarker for overall survival triple negative breast cancer within Tunisian patients2018
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation2017
Abstract A084: Identification of mutation-reactive T cells in patients with gastrointestinal cancers2016
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids2015
The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers2015
Abstract 5341: Bifunctional integrated molecules with combined retinoic acid receptor agonist/protein deacetylase inhibitory activities as therapeutic agents for breast cancer and neuroblastoma2015
A genome-wide shRNA screen to identify genes regulating ERα signalling and oestrogen-dependent proliferation in breast cancer cells2015
MicroRNAs Expression in Triple Negative vs Non Triple Negative Breast Cancer in Tunisia: Interaction with Clinical Outcome2014
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases’ occurrence2014
LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer2014
Abstract A55: Histone deacetylase inhibitors as differentiation agents in breast cancer cells2013